Teclistamab plus daratumumab significantly boosts survival for patients with early RRMM
- Study type
- Other
- Study name
- MajesTEC-3
- Source
- Cancer · 2026
In plain words
This news item reports on the MajesTEC-3 trial. According to its title, combining two drugs, teclistamab and daratumumab, significantly improved survival in patients with multiple myeloma whose disease had come back one to three times after initial treatment. Details, such as the exact size of the improvement and the side effects, are not included in this record. Be sure to talk to your treating doctor about whether this treatment is suitable for you.
Study population
The PubMed record has no abstract. Based on the title, the article concerns patients with relapsed/refractory multiple myeloma (RRMM) at first to third relapse after initial treatment. Inclusion criteria are not stated in this record.
Endpoints
Not stated in the PubMed record. The title only refers to a "significant survival boost".
Safety and side effects
The PubMed record contains no information on adverse events.
Clinical significance and place in guidelines
The available record has only a title and is not sufficient for clinical conclusions. The title indicates that this combination is the first test of a bispecific antibody in first to third relapse of multiple myeloma and that it increased survival. The status of drug approvals and guideline recommendations should be checked separately in primary sources. For exact data, the main report of the MajesTEC-3 trial should be consulted.
Limitations
This record has no abstract and its content is only the title of a news or commentary report. It contains no information on design, number of patients, doses, numerical results or adverse events, which must be taken from the main trial paper.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.